BioMed Research International

Review Article

Effectiveness of Platelet-Rich Fibrin as an Adjunctive Material to Bone Graft in Maxillary Sinus Augmentation: A Meta-Analysis of Randomized Controlled Trails

Table 2

(a) Outcome data of randomized controlled trials of the included studies.

Study

Year

Implant number

Sinus

Residual bone height (mm)

New bone formation

Residual graft particles

Soft tissue area

N—PRF

PRF

N—PRF

PRF

N—PRF

PRF

N—PRF

PRF

N—PRF

PRF

N—PRF

PRF

Nizam N

2018

2.53±0.61

2.45±0.79

21.25±5.59%

21.38± 8.78%

32.79± 5.89%

25.95 ±9.54%

45.96±8.36%

52.67±12.53%

Zhang Y

2012

Delayed implant placement

12.95±5.33%

18.35 ± 5.62%

28.54 ±12.01%

19.16±6.89%

Comert K S

2017

Delayed implant placement

33.40±10.43%

32.03±6.34%

30.39 ±10.29%

32.66 ±7.46%

36.21 ±10.59%

35.31 ±10.81%

Tatullo M

2012

Delayed implant placement

Gurler G

2016

Delayed implant placement

N-PRF: non-platelet-rich fibrin group; PRF: platelet-rich fibrin group; NA: not available. The percentage of newly formed bone (BV/TV); the percentage of residual bone graft (BSV/TV); the percentage of length of the profile of the bone graft in contact with new bone (bone-to-bone graft contact).

(b) Outcome data of randomized controlled trials of the included studies.


Study	Year	Contact between newly formed bone and bone substitute		Augmented bone Height (mm)		Survival rate		Complications (N—PRF/PRF)
Study	Year	N—PRF	PRF	N—PRF	PRF	N—PRF	PRF	Complications (N—PRF/PRF)

Nizam N	2018	54.04 ± 8.36%	47.33± 12.33%	13.53±1.20	13.60± 1.09	100%	100%	Bleeding (1/1) Sinus perforation (0/0)

Zhang Y	2012	18.57±5.39%	21.45± 14.57%	NA	NA	NA	NA	Inflammation (0/0)

Comert K S	2017	NA	NA	NA	NA	NA	NA	Schneiderian membrane perforation (2/2) No sinus infection

Tatullo M	2012	NA	NA	NA	NA	100%	100%	None

Gurler G	2016	NA	NA	NA	NA	NA	NA	Less swelling and pain in the PRF group